Our services
From evidence strategy to market access
Sur Access provides senior specialist support across clinical evidence, HTA, pricing and market access — from early development decisions through European launch.
The work follows one principle:
Clinical evidence → HTA outcome → probability of access → price → commercial value
Engagements range from defined fixed-price projects to larger strategic assignments tailored to the asset.
Learn
JCA Masterclass & Team Workshops
Scoped - book a call
Practical training for clinical, regulatory, medical and market-access teams navigating the new EU HTA environment.
- EU HTA and JCA: what changes for development teams
- PICO anticipation and evidence-gap analysis
- Comparator, endpoint and subgroup implications
- Real JCA and national HTA cases
- Practical application to your own development programmes
- Working checklists and frameworks for your team
Delivered in-house or as a live virtual programme.
Design
Access-Informed TPP for Biotech
CHF 6,500 - fixed price
Design the product profile around the access and value it needs to achieve.
A Target Product Profile should describe more than the product you hope to develop. It should test whether that product could deliver meaningful differentiation for regulators, HTA bodies, payers and the market.
The Access-Informed TPP brings those requirements into development early.
What we assess
- Target indication and patient population
- Current and future treatment landscape
- Relevant comparators
- Clinical differentiation and endpoints
- Subpopulations likely to matter for HTA
- Evidence required to support the intended value proposition
- Initial access, pricing and commercial implications
What you receive
A decision-focused TPP connecting the scientific, regulatory, access and commercial requirements of the future product — together with the key development questions that need to be resolved.
Best suited to: early clinical assets, development strategy reviews, investment preparation and partnering discussions.
Access-by-Design™ Trial Input
Scoped - book a call
Make the access decisions before the protocol makes them for you.
Expert market-access and HTA input before pivotal trial design or protocol lock.
We assess:
- Comparator choice
- Endpoints and endpoint hierarchy
- Patient population
- Clinically and HTA-relevant subgroups
- Statistical considerations with downstream HTA implications
- Likely European PICO requirements
- Direct and indirect comparative evidence needs
The objective is to identify development choices that could create future access problems — while those choices can still be changed.
Assess
EU Access Gap Analysis & Strategic Recommendations
CHF 9,500 - fixed price
Find the evidence gaps that matter — while there is still time to act.
Your existing clinical programme is stress-tested against the comparative evidence requirements likely to influence European HTA and market access.
What we assess
- Likely European PICOs
- Comparator alignment
- Endpoints and outcome hierarchy
- Population and relevant subpopulations
- Direct comparative evidence
- Feasibility and credibility of indirect comparisons
- Evidence certainty and key sources of uncertainty
- Regulatory–HTA alignment
- Important national HTA implications
What you receive
A prioritised strategic assessment showing:
What is covered.
Where the important gaps are.
What can still be addressed.
What may need to be managed rather than fixed.
Recommendations focus on the evidence gaps most likely to materially affect future HTA, access and commercial outcomes.
Because:
Not every evidence gap should be closed.
Only the ones worth more than they cost.
Execute
European Market Roadmap
CHF 18,000 - fixed price
Turn the evidence and value proposition into a route to market.
A focused four-week strategic assessment across:
Germany · France · Italy · Spain · United Kingdom
What we assess
- HTA and reimbursement pathway
- Relevant comparators
- Evidence expectations
- Likely positioning
- Pricing environment
- Key access risks
- Country-specific requirements
- Launch and sequencing considerations
What you receive
A practical European Market Entry Playbook with country-specific priorities and an action plan showing what needs to happen, when and why.
Designed for biotechnology companies approaching European development, partnering or launch decisions without a large internal market-access function.
JCA-Ready Dossier Support
Scoped - book a call
Strategic evidence support from JCA preparation through dossier development.
Support can include:
- PICO and comparator strategy
- Comparative evidence planning
- Direct and indirect treatment comparisons
- Population and subgroup strategy
- Evidence-certainty and uncertainty management
- Comparator justification
- Alignment with relevant CTD clinical sections
- JCA dossier strategy and review
- Preparation for downstream national HTA
Scope and resourcing are tailored to the asset and submission requirements.
Swiss Pricing & Reimbursement
Scoped - book a call
Strategy and execution for one of Europe's highest-value pharmaceutical markets.
Support across:
- Swiss price potential and pricing strategy
- APV and TQV positioning
- Comparator strategy
- SL dossier preparation and submission
- BAG engagement and reimbursement negotiations
- Art. 71 KVV early-access pathways
- Launch sequencing and international reference-pricing implications
Support can begin with early Swiss price and access strategy or continue through reimbursement execution.
A defined way to start
You do not need to commission a large consulting project to begin working with Sur Access.
Three fixed-price engagements provide defined entry points:
Access-Informed TPP
CHF 6,500
For assets where the future product and evidence strategy are still being designed.
EU Access Gap Analysis
CHF 9,500
For assets with an established clinical programme that need an HTA and access stress test.
European Market Roadmap
CHF 18,000
For assets preparing for European market entry, partnering or launch planning.
All other engagements are scoped around the asset, indication, development stage and decision to be made, with a fixed proposal agreed before work begins.
Not sure where to start?
Tell me where the asset is in development and what decision your team is facing.
